It Is Announced That Udine Wealth Management Inc. Has Invested $359,000 In Pfizer Inc.‍

Pfizer INC (NYSE: PFE) shares were acquired by Udine Wealth Management INC during the third quarter, according to a 13F filing with the Securities and Exchange Commission.

‍

Biopharmaceutical company shares were bought by an institutional investor for around $359,000.

‍

A total of $359,000 was spent on this project.

‍

Over the past quarter, Fagan Associates INC increased the percentage of Pfizer stock that it owns by 1.9%. Recent transactions have also affected a number of prominent investors' interests in the company.

‍

Following an additional 202 shares purchased during the most recent fiscal quarter by Fagan Associates INC, the company now holds 10,995 shares of stock.

‍

There is a $576,00 value on the stock at the moment.

‍

As a result of its improvements in Pfizer stock, HHM Wealth Advisors LLC saw its equity portfolio increase by 3.1% during the second quarter.

‍

A total of 6,685 shares are now owned directly by HHM Wealth Advisors LLC after making an additional investment of 203 shares during the most recent quarter.

‍

These shares are currently valued at $360,000 on the market.

‍

A 1.3% increase in Bridgeworth LLC's ownership of Pfizer stock occurred during the second quarter.

‍

An additional 203 shares in Bridgeworth LLC's biopharmaceutical company were acquired during the most recent quarter.

‍

This results in the company now owning 15,757 shares, which are valued at $826,000.

‍

As of the second quarter, Jackson Grant owned more Pfizer stock than it did in the first quarter, increasing its holdings to 1.8%.

‍

A total of 11,572 shares of the biopharmaceutical company have been acquired by Jackson Grant Investment Advisers INC since the most recent quarter.

‍

According to these shares, the company is doing quite well financially, with a total value of $607,000.

‍

To bring its ownership of Pfizer to 100%, Papp L. Roy & Associates increased its ownership by 0.8% in the second quarter.

‍

The biopharmaceutical company's stock reached a value of $1,318,000 as of the end of the current quarter, thanks to the accumulation of 25,145 shares by Papp L. Roy & Associates.

‍

Stocks of the company are currently owned by 67.62% of institutional investors, including hedge funds and other types of investors.

‍

For the day, PFE gained $0.38, reaching $43.72 in trading.

‍

There were 8,818,195 more transactions than average in this stock when compared to the average daily volume of 24,868,875.

‍

Stock prices for the company have been moving around $48.45 for the past 50 days and $47.48 for the past 200 days.

‍

A one-year high of $56.32 was reached by Pfizer INC during the period covered by this report, and a one-year low of $41.44 was recorded during the same period.

‍

These ratios range from 1.59 to 1.37 respectively for the debt-to-equity ratio, current ratio, and quick ratio in this example.

‍

With a price-to-growth ratio of 1.46, a price-to-earnings ratio of 7.91, and a beta value of 0.62, the company comes in as a value that has an excellent fundamental profile.

‍

A market capitalization of $245.41 billion is associated with the company at the moment.

‍

In its quarterly report, published online on January 31, Pfizer (NYSE: PFE) revealed its performance over the past quarter.

‍

A $0.11 increase in earnings per share (EPS) was reported for the biopharmaceutical sector for the period, up from earnings per share of $1.03 estimated by average analysts.

‍

Specifically, a $0.11 overperformance was seen in the industry.

‍

During the period, Pfizer had a return on equity of 43.02 percent and a net margin of 31.27 percent.

‍

Percentages are shown here.

‍

Its sales for the quarter were $24.30 billion, which is lower than the $24.40 billion that industry experts had predicted.

‍

Comparing the results of the same quarter last year with the results for the current quarter, the company reported a profit of $1.08 per share, an increase of 8%.

‍

The company reported a 1.9% increase in sales in the same quarter of last year, which contributed to a higher quarterly total.

‍

Pfizer Inc's earnings this year are expected to be $3.35 per share, according to equity analysts.

‍

Also, according to the business plan, a quarterly dividend will be distributed on March 3. Dividends of $0.41 will be paid to shareholders whose shares were registered on Friday, January 27, January 27, by the time the business day ended.

‍

In this case, the dividend payout is 1.64 dollars, resulting in a 3.75 percent dividend yield. In this case, the dividend payout is 1.64 dollars, resulting in a 3.75 percent dividend yield.

‍

Dividends distributed by Pfizer to shareholders every quarter have been increased from $0.40 to $0.50.

‍

As of Thursday, January 26, dividends will no longer be paid to shareholders.

‍

At the moment, Pfizer has a dividend payout ratio (DPR) of 29.93%.

‍

Research analysts and academic journals have extensively discussed PFE in a variety of papers.

‍

A research report published on February 1 by Barclays lowers the price objective from $49.00 to $44.00 for Pfizer shares and categorizes them as “equal weight.” StockNews.com changed the "buy" rating assigned to Pfizer's stock from a "buy" rating to a "strong-buy" rating on February 1, 2019.

‍

Despite Bank of America's recent upgrade to "neutral," the financial services company has set a $60 price target for Pfizer shares.

‍

The general public was informed about this in a written piece published on January 4.

‍

Pfizer was upgraded from a "neutral" rating to a "buy" rating by Goldman Sachs Group in a research report released on Tuesday, December 13.

‍

Pfizer's stock was changed in both of these ways.

‍

Wells Fargo & Company, a leading investment bank, downgraded Pfizer from an "overweight" to an "equal weight" ranking in a research report released on January 17.

‍

A $50.00 price target was set for the company, a decrease of $54.00.

‍

A final action by the company was to issue a buy recommendation for its stock. Six financial analysts have recommended it to investors, while eight have advised investors to keep their stock holdings.

‍

Stock analysts assign a consensus price objective to the stock of $51.81 as their price objective for this stock on Trade Algo, where it is currently rated "Hold" on average.

‍

A multinational biopharmaceutical company, Pfizer INC, conducts research at the moment.

‍

As well as manufacturing, marketing, and selling biopharmaceutical products, it takes part in research and development on a global scale.

‍

Through reducing illness, administering treatments, and discovering cures, the company aims to promote better health in developed and developing markets.